Clinical Trial Update: Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM) [Phase 2]

View source ↗

Summary

Phase II trial update for Anetumab Ravtansine as second-line treatment in malignant pleural mesothelioma has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Mesothelioma
• Mesothelioma

Drugs mentioned

• Anetumab Ravtansine (anetumab ravtansine)

Snippet

Sponsor: Bayer | Conditions: Mesothelioma | Phase 2 | Status: COMPLETED | Results posted: 2020-07-17